AbbVie (NYSE: ABBV) announced topline results from the Phase 3 EPCORE DLBCL-4 trial showing that epcoritamab combined with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE